Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 10/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496641 | 0.89 | MEN1 (0.44) | ABCG2POLBKDM4EGLAKMT2A | |
| SCHEMBL497281 | 0.86 | ABCG2 (0.46) | ABCG2PDE5APOLBKDM4EALDH1A1 | |
| SCHEMBL496490 | 0.83 | RXFP1 (0.43) | POLBKDM4ESMN1; SMN2 | |
| SCHEMBL496652 | 0.83 | ABCG2 (0.47) | ABCG2PDE5APOLBKDM4EALDH1A1 | |
| SCHEMBL496822 | 0.82 | ABCG2 (0.46) | ABCG2PDE5APOLBKDM4EALDH1A1 | |
| SCHEMBL2823225 | 0.80 | KDR (0.51) | POLBKDM4E | |
| SCHEMBL496538 | 0.80 | ABCG2 (0.58) | ABCG2PDE5APOLBKDM4EALDH1A1 | |
| SCHEMBL496579 | 0.80 | ABCG2 (0.44) | ABCG2PDE5APOLBKDM4EALDH1A1 | |
| SCHEMBL496929 | 0.80 | ABCG2 (0.44) | ABCG2PDE5APOLBKDM4EALDH1A1 | |
| SCHEMBL496627 | 0.78 | KDM4E (0.43) | POLBKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836207-B1 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2012-10-10 | — | — | EP | disclosed |
| US-8106047-B2 | (4-Methoxyphenyl)-[3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine; phosphodiesterase inhibitors; septic shock or vascular edema; neoangiogenesis or inflammatory disease | NYCOMED GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080312225-A1 | Triazolophthalazines | NYCOMED GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312225-A1 | Triazolophthalazines | PDE2A, PDE3A, PDE12 | ABCG2 2008/4885PDE5A 4/4885POLB 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.